Amgen’s Immuno-Oncology Strategy Hinges On T-VEC’s Mechanism, Combinability
This article was originally published in The Pink Sheet Daily
Executive Summary
Awaiting FDA approval for monotherapy in metastatic melanoma, Amgen uses ASCO to launch new combination studies with Merck and Roche immune checkpoint inhibitors, adding to one ongoing with Bristol’s Yervoy.